Cerebrospinal fluid vitamin D-binding protein as a new biomarker for the diagnosis of meningitis

Lee, Dong-Hyun; Kang, Heeyoung; Kim, Jin Hyun; Jung, Myeong Hee; Cho, Min-Chul

doi:10.1007/s10072-019-03873-9

Cited by 10 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VitD has also been examined as a late-stage therapy for stroke, with conflicting outcomes despite high-quality data [97]. VitD and VitD binding protein have been discussed as potential biomarkers in patients with stroke [98], MS [99], AD [100], glioblastoma [101], traumatic brain injury [102], and meningitis [103].…”

Section: Discussionmentioning

confidence: 99%

The Role of Vitamin D in Basal Ganglia Diseases

Homann¹,

Homann²

2022

J. Integr. Neurosci.

View full text Add to dashboard Cite

Objective: Vitamin D (VitD) has been shown to influence several cellular processes in the brain. The extent to which VitD plays a role in the pathomechanism of neuronal loss and dysfunction in basal ganglia diseases (BGDs) is still debated. There is yet to be a comprehensive study that provides an overview of all of the most relevant BGDs. Methods: PubMed, and Google Scholar were systematically searched for observational studies that investigated the association between serum VitD levels and BGDs up to March 2022. Results: We extracted 60 studies, but with a great variety of design and quality. VitD deficiency appears to be common in most BGDs, but only in Parkinson's disease (PD) has a causal association been fully examined. There is some evidence that low VitD serum levels influence symptom severity, most notably in restless legs syndrome (RLS), PD, and tic disorders. The effects of vitamin D supplementation were studied in three BGDs, with results mostly favorable for RLS, ambiguous for tics, and mostly unfavorable for PD. Conclusions: There are still various elements of BGDs with insufficient, ambiguous, or altogether absent evidence, and further high-quality research is required. However, there appears to be sufficient scientific justification already to recommend that practitioners treating BGDs check serum VitD levels and supplement as appropriate.

show abstract

Section: Discussionmentioning

confidence: 99%

The Role of Vitamin D in Basal Ganglia Diseases

Homann¹,

Homann²

2022

J. Integr. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Recent results indicate that only 2% of DBP functions as a vitamin binder, while its main effect is to modulate inflammation [ 50 ]. DBP is detectable in serum and cerebrospinal fluid [ 51 ], and it functions as a precursor of GcMAF, a protein driving macrophage activation, switching them into a proinflammatory phenotype. DBP transformation into GcMAF is promoted by B and T lymphocytes and is mediated by a cascade of carbohydrate processing reactions [ 52 , 53 ].…”

Section: Discussionmentioning

confidence: 99%

GC1f Vitamin D Binding Protein Isoform as a Marker of Severity in Autism Spectrum Disorders

et al. 2022

View full text Add to dashboard Cite

Autism spectrum disorders (ASD) are characterized by a wide spectrum of clinical, behavioral, and cognitive manifestations. It is, therefore, crucial to investigate possible biomarkers associated with specific ASD phenotypes. Ample literature suggests a possible role for vitamin D (VD) in influencing ASD clinical phenotypes. We analyzed three vitamin D binding protein gene (DBP) functional polymorphisms (rs2282679, rs7041, and rs4588), which are involved in the modulation of vitamin D serum concentration in 309 ASD children and 831 healthy controls. Frequency comparisons of single nucleotide polymorphisms (SNPs) alleles, genotypes, and GC isoforms (GC1f, G1s, and GC2)—generated by the combination of rs7041 and rs4588 alleles—were correlated with ASD diagnostic, behavioral, and functioning scales. The GC1f isoform was significantly more frequent in ASD compared with controls (18.6% vs. 14.5% pc = 0.02). Significantly higher scores for item 15 of the Childhood Autism Rating Scale (CARS) and lower ones for the Children’s Global Assessment Scale (CGAS) functioning scales were seen in ASD carrying the GC1f isoform. In GC phenotype analysis, a gradient of severity for overall CARS scores and CARS item 15 was observed, with scores decreasing according to the presence of GC1f-GC1f > GC1f-GC1s > GC1s-GC1s > GC1f-GC2 > GC2-GC2 isoforms. Similarly, lower CGAS scores were seen in carriers of the GC1f-GC1f isoform, whereas higher scores were present in those carrying GC2-GC2 (p = 0.028). This is the first study to evaluate possible relationships between GC variants and the different aspects of ASD in Italian ASD children. Results, although needing to be validated in ampler cohorts, suggest that the GC1f isoform could be a marker of severity in ASD that may be useful in establishing the intensity of therapeutic and rehabilitative protocols.

show abstract

“…It is also noteworthy that DBP is found in cerebrospinal fluid (CSF), so vitamin D metabolites are likely to bind to this. However, the expression of DBP in the CNS is influenced by different pathological conditions (e.g., multiple sclerosis, meningitis) [51], so the free fractions of calcidiol and calcitriol may fluctuate and are very difficult to quantify.…”

Section: Transport and Cellular Uptake Of Vitamin Dmentioning

confidence: 99%

Role of Vitamin D in Cognitive Dysfunction: New Molecular Concepts and Discrepancies between Animal and Human Findings

Gáll

Székely

2021

Nutrients

View full text Add to dashboard Cite

Purpose of review: increasing evidence suggests that besides the several metabolic, endocrine, and immune functions of 1alpha,25-dihydroxyvitamin D (1,25(OH)2D), the neuronal effects of 1,25(OH)2D should also be considered an essential contributor to the development of cognition in the early years and its maintenance in aging. The developmental disabilities induced by vitamin D deficiency (VDD) include neurological disorders (e.g., attention deficit hyperactivity disorder, autism spectrum disorder, schizophrenia) characterized by cognitive dysfunction. On the other hand, VDD has frequently been associated with dementia of aging and neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s disease). Recent findings: various cells (i.e., neurons, astrocytes, and microglia) within the central nervous system (CNS) express vitamin D receptors (VDR). Moreover, some of them are capable of synthesizing and catabolizing 1,25(OH)2D via 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1) and 25-hydroxyvitamin D 24-hydroxylase (CYP24A1) enzymes, respectively. Both 1,25(OH)2D and 25-hydroxyvitamin D were determined from different areas of the brain and their uneven distribution suggests that vitamin D signaling might have a paracrine or autocrine nature in the CNS. Although both cholecalciferol and 25-hydroxyvitamin D pass the blood–brain barrier, the influence of supplementation has not yet demonstrated to have a direct impact on neuronal functions. So, this review summarizes the existing evidence for the action of vitamin D on cognitive function in animal models and humans and discusses the possible pitfalls of therapeutic clinical translation.

show abstract

Cerebrospinal fluid vitamin D-binding protein as a new biomarker for the diagnosis of meningitis

Cited by 10 publications

References 37 publications

The Role of Vitamin D in Basal Ganglia Diseases

The Role of Vitamin D in Basal Ganglia Diseases

GC1f Vitamin D Binding Protein Isoform as a Marker of Severity in Autism Spectrum Disorders

Role of Vitamin D in Cognitive Dysfunction: New Molecular Concepts and Discrepancies between Animal and Human Findings

Contact Info

Product

Resources

About